FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Multiple Violations Found in Capillus Inspection

[ Price : $8.95]

FDAs Florida District Office warns Capillus about Quality System, Medical Device Reporting, and other violations in its manufactur...

Viiv Submitting HIV Drug NDA

[ Price : $8.95]

Viiv Healthcare says it is submitting an NDA for a combination HIV-1 drug based on its Tivicay and two other antiretrovirals.

Latest Warning Letters

[ Price : $8.95]

In its latest batch of Warning Letters, FDA cites Capillus, Dolphin Intertrade, Omid Nassam, R82 A/S. Dimitri Sirakoff, USP Labs, ...

FDA OKs New Dosage Strengths for Antara

[ Price : $8.95]

FDA approves a Lupin supplemental NDA for Antara (fenofibrate) capsules in 30 mg and 90 mg strengths, indicated for treating patie...

Cubist Files NDA for New Antibiotic

[ Price : $8.95]

Cubist Pharmaceuticals submits an NDA for its investigational antibiotic tedizolid phosphate, indicated for treating acute bacteri...

Pfizer Proceeding with Remoxy NDA After Meeting with FDA

[ Price : $8.95]

Durect Corp. says its development partner Pfizer will continue the development program for Remoxy (oxycodone) extended-release cap...

Stakeholders Have Many Concerns on Device Reporting Draft

[ Price : $8.95]

Stakeholders raise many questions and concerns about an FDA draft guidance on medical device reporting by manufacturers.

Curis, Debiopharm Start Phase 1 Study in Renal Cell Carcinoma

[ Price : $8.95]

Curis Inc. and Debiopharma begin a Phase 1 study of Debio 0932, a heat shock protein 90 inhibitor in combination with everolimus i...

Orphan Drug Designation for Pancreatic Cancer Therapy

[ Price : $8.95]

FDA grants Aduro BioTech an orphan drug designation for CRS-207 for treating pancreatic cancer.

FDA Reviewers Generally Positive on Simeprevir

[ Price : $8.95]

FDA medical reviewers says Janssens experimental hepatitis C drug simeprevir appears to be effective but has some side effects.